Clinical Trial Update: Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy [Phase 3]

View source ↗

Summary

The ESPRIT TOXIL-2 toxicity substudy evaluating subcutaneous aldesleukin in HIV infections has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Proleukin (aldesleukin)

Snippet

Sponsor: Kirby Institute | Conditions: HIV Infections | Phase 3 | Status: TERMINATED